Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors.

Méndez-Blanco C, Fondevila F, García-Palomo A, González-Gallego J, Mauriz JL. · 2018

Read Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. by Méndez-Blanco C, Fondevila F, García-Palomo A, González-Gallego J, Mauriz JL. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6185986.txt.

Description

Méndez-Blanco and co-authors wrote a review in Experimental and Molecular Medicine on sorafenib resistance in liver cancer. Sorafenib is a multi-action drug and the standard first-line treatment for advanced hepatocellular carcinoma. It slows growth, cuts blood supply, and promotes tumor cell death. Long-term success is low because resistant cells emerge.

The review focuses on hypoxia-inducible factors, proteins that respond to low oxygen. By shrinking tumor vessels, sorafenib itself deepens oxygen shortage. Hypoxia programs then select cells that thrive in that setting. High HIF-1 alpha and HIF-2 alpha mark poor outlook in patients. The authors map this feedback loop and what it means for future combination treatments.

Catalog record

CREATORMéndez-Blanco C, Fondevila F, García-Palomo A, González-Gallego J, Mauriz JL.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE38 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6185986

Browse the full library · About the Tower of Babel